Phaseline

Companies › Pharosgen

Pharosgen: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
MPD-1
Doxorubicin prodrug targeting KRAS mutant/PTEN loss advanced cancer
KRAS, PTENPhase 1CancerDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06944457MPD-1Phase 1CancerOncologyDec 2026

Targets

KRAS (1) PTEN (1)

Companies with the same targets

Revolution Medicines TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) Amgen Quanta Therapeutics Roche Eli Lilly Bristol-Myers Squibb Novartis Astellas Abbisko Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.